AnaptysBio, Inc.
ANAB
$18.24
-$1.05-5.44%
| Weiss Ratings | ANAB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D- | |||
| Reward Grade | E | |||
| Rating Factors | ANAB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Fair | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Good | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | ANAB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.12 | |||
| Price History | ANAB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 0.27% | |||
| 30-Day Total Return | -1.88% | |||
| 60-Day Total Return | 22.99% | |||
| 90-Day Total Return | -13.84% | |||
| Year to Date Total Return | 36.53% | |||
| 1-Year Total Return | -14.37% | |||
| 2-Year Total Return | -15.94% | |||
| 3-Year Total Return | -28.33% | |||
| 5-Year Total Return | 19.53% | |||
| 52-Week High % Change | -53.30% | |||
| 52-Week Low % Change | 57.99% | |||
| Price | ANAB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $41.31 | |||
| 52-Week Low Price | $12.21 | |||
| 52-Week Low Price (Date) | Feb 11, 2025 | |||
| 52-Week High Price (Date) | Aug 14, 2024 | |||
| Valuation | ANAB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 591.56M | |||
| Enterprise Value | 575.65M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -5.20 | |||
| Earnings Per Share Growth | -14.41% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 6.43 | |||
| Price/Book (Q) | 8.29 | |||
| Enterprise Value/Revenue (TTM) | 6.31 | |||
| Price | $18.24 | |||
| Enterprise Value/EBITDA (TTM) | -5.03 | |||
| Enterprise Value/EBIT | -5.01 | |||
| Market Cap Category | Small Cap | |||
| Dividends and Shares | ANAB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 30.45M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | ANAB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 858 362 6295 | |||
| Address | 10770 Wateridge Circle San Diego, CA 92121-5801 | |||
| Website | www.anaptysbio.com | |||
| Country | United States | |||
| Year Founded | 2005 | |||
| Profitability | ANAB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -125.93% | |||
| Profit Margin | -159.10% | |||
| Management Effectiveness | ANAB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -15.35% | |||
| Return on Equity | -- | |||
| Income Statement | ANAB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 91.28M | |||
| Total Revenue (TTM) | 91.28M | |||
| Revenue Per Share | $3.00 | |||
| Gross Profit (TTM) | -72.56M | |||
| EBITDA (TTM) | -114.34M | |||
| EBIT (TTM) | -114.95M | |||
| Net Income (TTM) | -145.23M | |||
| Net Income Avl. to Common (TTM) | -145.23M | |||
| Total Revenue Growth (Q YOY) | 378.77% | |||
| Earnings Growth (Q YOY) | 48.39% | |||
| EPS Diluted (TTM) | -5.20 | |||
| EPS Diluted Growth (Q YOY) | 54.94% | |||
| Balance Sheet | ANAB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 385.37M | |||
| Cash Per Share (Q) | $12.66 | |||
| Total Current Assets (Q) | 431.88M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 70.87M | |||
| Current Ratio (Q) | 9.507 | |||
| Book Value Per Share (Q) | $2.33 | |||
| Total Assets (Q) | 483.83M | |||
| Total Current Liabilities (Q) | 45.43M | |||
| Total Debt (Q) | 369.46M | |||
| Total Liabilities (Q) | 412.97M | |||
| Total Common Equity (Q) | 70.87M | |||
| Cash Flow | ANAB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | 95.40M | |||
| Cash from Financing (TTM) | 127.05M | |||
| Net Change in Cash (TTM) | 87.12M | |||
| Levered Free Cash Flow (TTM) | -89.79M | |||
| Cash from Operations (TTM) | -135.34M | |||
